<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006945</article-id><article-id pub-id-type="pmc">PMC11860742</article-id><article-id pub-id-type="doi">10.3390/v17020190</article-id><article-id pub-id-type="publisher-id">viruses-17-00190</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>DNA-Binding Activities of KSHV DNA Polymerase Processivity Factor (PF-8) Complexes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Travis</surname><given-names>Jennifer Kneas</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-17-00190" ref-type="aff">1</xref><xref rid="af2-viruses-17-00190" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Megan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-17-00190" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3516-0317</contrib-id><name><surname>Costantini</surname><given-names>Lindsey M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-17-00190" ref-type="aff">1</xref><xref rid="c1-viruses-17-00190" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Gonnella</surname><given-names>Roberta</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00190"><label>1</label>Department of Biological and Biomedical Sciences, North Carolina Central University, Durham, NC 27707, USA; <email>jkneas@eagles.nccu.edu</email> (J.K.T.); <email>mmarti64@nccu.edu</email> (M.M.)</aff><aff id="af2-viruses-17-00190"><label>2</label>Integrated Biosciences (INBS) Doctoral Program, North Carolina Central University, Durham, NC 27707, USA</aff><author-notes><corresp id="c1-viruses-17-00190"><label>*</label>Correspondence: <email>lmcostantini@nccu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>190</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Kaposi&#x02019;s Sarcoma Herpesvirus (KSHV) is the causative agent of several human diseases. There are few effective treatments available to treat infection and KSHV oncogenesis. Disrupting the KSHV infectious cycle would diminish the viral spread. The KSHV lytic phase and production of new virions require efficient copying and packaging of the KSHV genome. KSHV encodes its own lytic DNA replication machinery, including the processivity factor (PF-8), which presents itself as an attractive target for antiviral development. We characterized PF-8 at the single molecule level using transmission electron microscopy to identify key molecular interactions that mediate viral DNA replication initiation. Our results indicate that PF-8 forms oligomeric ring structures (tetramer, hexamer, and/or dodecamer) similar to the related Epstein&#x02013;Barr virus processivity factor (BMRF1). Our DNA positional mapping revealed high-frequency binding locations of PF-8 within the lytic origin of replication (OriLyt). A multi-variable analysis of PF-8 DNA-binding activity with three mutant OriLyts provides new insights into the mechanisms that PF-8 associates with viral DNA and complexes to form multi-ring-like structures. Collectively, these data enhance the mechanistic understanding of the molecular interactions (protein&#x02013;protein and protein-DNA) of an essential KSHV DNA replication protein.</p></abstract><kwd-group><kwd>KSHV</kwd><kwd>HHV-8</kwd><kwd>viral replication</kwd><kwd>electron microscopy</kwd><kwd>human herpesviruses</kwd></kwd-group><funding-group><award-group><funding-source>National Institutes of Health (NIH), NIGMS</funding-source><award-id>R16GM153198</award-id><award-id>SC2GM136527</award-id></award-group><funding-statement>This research was funded by the National Institutes of Health (NIH), NIGMS, grant number R16GM153198 and SC2GM136527.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00190"><title>1. Introduction</title><p>Kaposi&#x02019;s Sarcoma Herpesvirus (KSHV) is a part of the gamma subfamily of the Herpesviridae family along with Epstein&#x02013;Barr Virus (EBV) [<xref rid="B1-viruses-17-00190" ref-type="bibr">1</xref>]. The Herpesviridae family consists of large linear double-stranded DNA genomes that are encompassed by an icosahedral capsid and consist of an envelope that has many viral glycoproteins [<xref rid="B2-viruses-17-00190" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00190" ref-type="bibr">3</xref>]. KSHV is the causative agent of Kaposi&#x02019;s sarcoma (KS), multicentric Castleman&#x02019;s disease, primary effusion lymphoma, and KSHV inflammatory cytokine syndrome [<xref rid="B3-viruses-17-00190" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00190" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00190" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-00190" ref-type="bibr">6</xref>]. KSHV is most prevalent in African and Mediterranean regions [<xref rid="B7-viruses-17-00190" ref-type="bibr">7</xref>]. The mode of transmission may vary in different regions and KSHV can infect a broad range of cell types including endothelial cells, epithelial cells, B-cells, monocytes, and keratinocytes [<xref rid="B3-viruses-17-00190" ref-type="bibr">3</xref>,<xref rid="B7-viruses-17-00190" ref-type="bibr">7</xref>]. There are few effective treatments available for KSHV because of several difficulties such as side effects and limited efficacy; however, there are ongoing efforts to discover antivirals that target the KSHV lifecycle [<xref rid="B8-viruses-17-00190" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00190" ref-type="bibr">9</xref>].</p><p>KSHV like all herpesviruses exists in a biphasic state: latent (dormant) and lytic (active) [<xref rid="B10-viruses-17-00190" ref-type="bibr">10</xref>]. Both phases contribute to oncogenesis through various mechanisms such as proliferation, angiogenesis, and inflammation [<xref rid="B11-viruses-17-00190" ref-type="bibr">11</xref>]. The lytic phase is when new virions are produced and more specifically this is when the viral genome is replicated by a set of lytic DNA replication proteins that are encoded by KSHV [<xref rid="B12-viruses-17-00190" ref-type="bibr">12</xref>]. The lytic DNA replication proteins are encoded by ORF50 (origin binding protein/RTA), ORF9 (DNA polymerase/POL), ORF44 (helicase), ORF6 (single-stranded binding protein), ORF40/41 (primase associated factor), ORF56 (primase), and ORF59 (processivity factor/PF-8) [<xref rid="B12-viruses-17-00190" ref-type="bibr">12</xref>]. Some of these proteins are known to associate with one another and form subcomplexes [<xref rid="B13-viruses-17-00190" ref-type="bibr">13</xref>]. In addition to the seven crucial lytic DNA replication proteins, there are two lytic origins of replication (OriLyt). Previous studies have identified the motifs shared between the two sequences, which are an AT-rich region, AT-palindrome, TATA boxes, RTA responsive element (RRE) site, and AP-1 and CAAT binding sequences [<xref rid="B14-viruses-17-00190" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00190" ref-type="bibr">15</xref>]. The OriLyts also share a GC-rich repetitious region [<xref rid="B14-viruses-17-00190" ref-type="bibr">14</xref>]. Currently, there are two proposed mechanisms for how the pre-initiation DNA replication complex forms. One mechanism proposes that the KSHV DNA replication proteins associate together in solution and subsequently bind to the OriLyt. The second mechanism proposes that the origin binding proteins (RTA and K8) associate with the OriLyt and recruit other proteins to the area to form the pre-initiation complex on DNA [<xref rid="B16-viruses-17-00190" ref-type="bibr">16</xref>]. In addition to viral proteins, cellular proteins such as topoisomerases, RecQL, and Ku86/70 autoantigens are important for the formation of the pre-initiation complex [<xref rid="B16-viruses-17-00190" ref-type="bibr">16</xref>].</p><p>Processivity factors are one of many proteins involved in forming the pre-initiation complex and are required for the efficient replication of the viral genome. The main function of processivity factors is to help keep DNA polymerase bound to DNA so that the 165-170 kilobase KSHV genome can be synthesized efficiently [<xref rid="B17-viruses-17-00190" ref-type="bibr">17</xref>,<xref rid="B18-viruses-17-00190" ref-type="bibr">18</xref>]. Without PF-8, the DNA polymerase is only capable of incorporating three nucleotides before DNA polymerase dissociates from the DNA further emphasizing the importance that PF-8 plays in lytic DNA replication [<xref rid="B17-viruses-17-00190" ref-type="bibr">17</xref>]. PF-8 encodes several functional domains including dimerization, double-stranded DNA binding, DNA polymerase binding, and a nuclear localization signal [<xref rid="B19-viruses-17-00190" ref-type="bibr">19</xref>]. Each of those domains serves a critical role in lytic DNA replication [<xref rid="B20-viruses-17-00190" ref-type="bibr">20</xref>]. The crystal structure of a truncated PF-8 isolated from an <italic toggle="yes">E. coli</italic> expression system revealed the formation of dimers by head-to-head association, while a study with cell lysate from reactivated iSLK BAC 16 cells suggests that PF-8 is capable of forming a tetramer [<xref rid="B19-viruses-17-00190" ref-type="bibr">19</xref>,<xref rid="B21-viruses-17-00190" ref-type="bibr">21</xref>]. There are several outstanding questions we seek to investigate using our imaging approach.</p><p>The goal of this study is to characterize purified full-length PF-8 at the single molecule level using transmission electron microscopy (TEM). We have successfully applied similar approaches to show RTA binds to specific DNA sequences as a dimer and throughout the OriLyt as a monomer [<xref rid="B22-viruses-17-00190" ref-type="bibr">22</xref>]. The advantage of utilizing electron microscopy is that it allows for heterogeneous populations to be observed. We utilized two different electron microscopy approaches: negative staining to observe protein conformations and tungsten rotary shadowing to analyze PF-8&#x02019;s position on OriLyt DNA and protein area in the presence and absence of DNA [<xref rid="B23-viruses-17-00190" ref-type="bibr">23</xref>,<xref rid="B24-viruses-17-00190" ref-type="bibr">24</xref>]. We characterized the oligomeric state of PF-8 in the presence and absence of viral DNA. Our data suggest that PF-8 can form multiple oligomeric states with some complexes larger than a tetramer. We identified several PF-8 binding locations within the OriLyt and generated three mutant OriLyt DNAs to further characterize PF-8&#x02019;s preferential binding. PF-8 has been previously shown to associate with the CAAT and RRE regions within the OriLyt [<xref rid="B25-viruses-17-00190" ref-type="bibr">25</xref>,<xref rid="B26-viruses-17-00190" ref-type="bibr">26</xref>]. Our data provides evidence that PF-8 can preferentially bind to regions encoding CAAT sites; however, our mutant DNA templates suggest a DNA structural specificity as well. Similar to our findings with RTA, we observed DNA-binding preferences for the different PF-8 oligomers. By helping provide a comprehensive characterization of PF-8 at the single molecule level, we hope to provide a better understanding of PF-8&#x02019;s role in DNA replication and thus provide a more targeted approach for the development of antivirals against KSHV.</p></sec><sec id="sec2-viruses-17-00190"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-17-00190"><title>2.1. Biotin End-Labeling of DNA</title><p>The OriLyt was synthesized from GeneArt (ThermoFisher, Waltham, MA, USA) and was subcloned into either pRSET or poxGFP-N1 [<xref rid="B22-viruses-17-00190" ref-type="bibr">22</xref>]. Approximately 80 units of XhoI (New England Biolabs, Ipswich, MA, USA) was digested for 1 h at 37 &#x000b0;C with the OriLyt to create a 5&#x02032; overhang. The restriction enzyme was then heat-inactivated, and 20 units of Klenow Exo-Polymerase (New England Biolabs), 2.8 &#x000b5;M of biotin 14-CTP, and 37&#x000b5;M of dATP, dGTP, and dTTP were added and incubated for 1 h at 37 &#x000b0;C. Subsequently, the polymerase was heat-inactivated, and either 80 units of NdeI (OriLyt-R poxGFP-N1) or NdeI and ScaI (OriLyt-R pRSET) were added and incubated at 37 &#x000b0;C for 1 h. The samples were then run on a 0.5 or 1.0% agarose gel cast with GelRed Nucleic Acid Stain (Biotium, Fremont, CA, USA), and the approximate 2.4kb (OriLyt-R) band was excised and purified with the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) following manufacturer&#x02019;s instructions. DNA concentrations were determined using the Nanodrop 2000c spectrophotometer (ThermoScientific, Waltham, MA, USA).</p></sec><sec id="sec2dot2-viruses-17-00190"><title>2.2. Site-Directed Mutagenesis of Lytic Origins of Replication</title><p>To introduce mutations, a shuttle vector was engineered for the OriLyt that used restriction sites PstI and XhoI, flanking a 1.28 kb region of the OriLyt that was subcloned into poxGFP-N1. Mutagenesis was performed in the shuttle vector. The mutagenesis primers used are listed in <xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Table S1</xref> and were designed to mutate certain CAAT sites or a TATA box within the OriLyt. Site-directed mutagenesis was performed with Pfu polymerase according to the manufacturer&#x02019;s instructions (Agilent Technologies, Santa Clara, CA, USA). Following site-directed mutagenesis PCR, the PCR reaction was incubated with DpnI (New England Biolabs) for 1 h at 37 &#x000b0;C. Subsequently, PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) and transformed into DH5&#x003b1; component cells (ThermoFisher) following the manufacturer&#x02019;s instructions. Several clones were cultured, and the DNA was isolated with the GeneJET Plasmid Miniprep Kit (ThermoFisher). Once mutations were sequence verified, the positive clones were transformed with standard cloning techniques, subcultured, and DNA was isolated with the Qiagen Plasmid Midi Kit (Qiagen). The sequence-verified mutated DNA was subcloned back into the full-length OriLyt vector and sequenced to confirm successful cloning. Two triple-mutants (mutant 1 and 2) and one six-point mutant (mutant 3) were generated using the outlined methods.</p></sec><sec id="sec2dot3-viruses-17-00190"><title>2.3. Denaturing and Semi-Native Gel Electrophoresis</title><p>PF-8 was expressed and purified from Sf9 insect cells (ThermoFisher). Briefly, Sf9 cells were harvested 48 h post-infection and PF-8 was isolated using a HisTrap (Waltham, MA, USA) column with a linear gradient (20&#x02013;500 mM imidazole in 25 mM Tris, 500 mM NaCl). The His-tag was cleaved using a TEV protease, and the TEV protease was removed using Dynabeads (Waltham, MA, USA). PF-8 was then dialyzed against PBS for 16 h. Purified PF-8 was aliquoted and flash-frozen using liquid nitrogen and stored at &#x02212;80 &#x000b0;C. Glutamine synthetase (GS) was expressed and purified from <italic toggle="yes">E. coli</italic> (Sigma Aldrich, St. Louis, MO, USA). GS was reconstituted to a concentration of 608 ng/&#x000b5;L according to the manufacturer&#x02019;s recommendations in water, aliquoted, flash frozen, and stored at &#x02212;80 &#x000b0;C. Approximately 4.0 &#x000b5;g of PF-8 or GS was added to 1&#x000d7; Laemmli sample buffer with 2.5% BME (Biorad, Hercules, CA, USA) or 1&#x000d7; semi-native loading buffer (31.3 mM Tris, 0.005% bromo blue, 0.1% SDS, and 20% glycerol). Samples that contained Laemmli sample buffer were incubated at 95 &#x000b0;C for 10 min and vortexed. For the semi-native gel, a 4&#x02013;20% Mini-Protean TGX Stain-free protein gel (Biorad) was pre-run at 70 V for 20 min with 1&#x000d7; TG buffer on ice. Samples and ladder (NativeMark unstained protein standard, Invitrogen (Waltham, MA, USA)) were loaded into the gel and run for 20 min at 70 V and then for 100 V for 4 to 5 h. For the denaturing gel, the samples and ladder (Precision Plus Protein Kaleidoscope, Biorad) were loaded into a 4&#x02013;20% Mini-Protean TGX Stain-free protein gel (Biorad) and run for 100 V until the dye front was at the bottom of the gel. To stain the polyacrylamide gels, the gels were microwaved for 1 min in deionized water twice with a water exchange and then microwaved for 30 s with Coomassie stain (0.05% R-250, 50% methanol, and 10% acetic acid). The gels were incubated with the Coomassie stain for 15 min at room temperature and were destained with deionized water overnight. Images of the gels were taken using the Chemidoc MP Imaging system (Biorad).</p></sec><sec id="sec2dot4-viruses-17-00190"><title>2.4. Negative Staining of PF-8</title><p>For negative staining, PF-8 was diluted in 20 mM HEPES and 150 mM NaCl to concentrations of 1&#x02013;30 ng/&#x000b5;L. Carbon-coated 400-cooper mesh grids were glow-discharged for 2 min at 150&#x02013;200 torr. Next, 15 &#x000b5;L of PF-8 protein was absorbed onto the glow-discharged grids for 5 min. The grid was stained with 1&#x02013;2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) uranyl acetate diluted in water and dried on filter paper. TEM images were obtained using a FEI Tecnai 12 electron microscope at 80 kV with 26,000&#x02013;60,000&#x000d7; magnification and captured on a Gatan First Light CCD camera using Gatan Digital Micrograph software version 1.85.1535 (Gatan, Pleasanton, CA, USA).</p></sec><sec id="sec2dot5-viruses-17-00190"><title>2.5. Tungsten Rotary Shadowing of Purified Proteins and DNAs</title><p>For the condition of PF-8 at 4 &#x000b0;C, PF-8 was diluted to a final concentration of 2 ng/&#x000b5;L in EM buffer (20 mM HEPES, 50 mM NaCl, 0.1 mM EDTA, 0.5 mM DTT) and incubated on ice for at least 2 h. For all other PF-8 conditions, PF-8 was diluted in EM buffer to a final concentration of 54.8 ng/&#x000b5;L. For increasing incubation time, 200 ng of PF-8 was incubated with EM buffer for 30 min, 1 h, 2 h, or 3 h at room temperature and then absorbed onto glow-discharged, carbon-coated copper mesh grids. For increasing concentrations 100 ng, 200 ng, 400 ng, or 800 ng of PF-8 was combined with EM buffer and incubated for 1 h at room temperature before being absorbed onto the glow-discharged, carbon-coated copper mesh grids. GS was diluted in water to a final concentration of 101.3 ng/&#x000b5;L and incubated on ice for 1 h. Subsequently, 200 ng of GS was absorbed onto glow-discharged, carbon-coated copper mesh grids.</p><p>For DNA-binding reactions, 200 ng of biotin-labeled DNA and EM buffer were incubated at room temperature for 10 min. PF-8 was diluted in EM buffer to a final concentration of 43.2 ng/&#x000b5;L. Then, 1080 ng of PF-8 was added to the DNA reaction and incubated at room temperature for 30 min. For fixed samples, 0.3% glutaraldehyde was added next, incubated for 15 min at room temperature, and quenched with 0.1 mM Tris. In order to label the DNA, 0.01 mg/mL of streptavidin was added and incubated for at least 15 min at room temperature. A size exclusion column was prepared with 6% agarose beads (Agarose Bead Technologies, Torrej&#x000f3;n de Ardoz, Spain) and equilibrated with TE (10mM Tris-base (pH 7.6), 1mM EDTA with LC/MS water) for 30 min. The DNA&#x02013;protein reaction was then added to the column and the void volume for the column was collected and discarded. Subsequently, fractions (2 drops) were collected and measured using Qubit dsDNA HS Assay Kit (ThermoFisher) following the manufacturer&#x02019;s instructions to identify fractions to be mounted for TEM.</p><p>Carbon-coated 400-cooper mesh grids (Electron Microscopy Sciences, EMS, Hatfield, PA, USA) grids were glow-discharged for 45 s. Fractions from the size exclusion column that contained the highest DNA concentration according to Qubit were mixed with 2 mM spermidine and absorbed onto the glow-discharged grids for 5 min. The grids were then quickly rinsed in a dish containing ultrapure LC/MS water and placed in another dish of LC/MS water for 3 min. Subsequently, the grid was placed in increasing concentrations of ethanol (25%, 50%, 75%, and 100%) for 5 min each. The grids were then either shadowed the same day or stored at room temperature until shadowing could be performed. For shadowing, the grids were shadowed with evaporated tungsten until the deposition monitor reached 0.65 k&#x000c5;. The grids were then immediately imaged or stored in a vacuum desiccator (Pelco 2251 Vacuum Desiccator) until imaging the next day. Imaging was performed with the Philips CM12 TEM microscope with Gatan Orius charged couple camera and Gatan Digital Micrograph Software was used to acquire images. The TEM microscope was set to 40 kV and 13,000&#x000d7; magnification for samples shadowed with tungsten.</p></sec><sec id="sec2dot6-viruses-17-00190"><title>2.6. Quantification of DNA Structures</title><p>Grids that contained wild-type or mutant 1&#x02013;3 OriLyt DNA with PF-8 were imaged using a Philips CM12 TEM microscope, and roughly 400 DNA molecules per replicate were counted by choosing multiple fields of view on the grid and quantifying the different DNA and protein conformations. For each experiment, two grids were examined for each replicate of the wild-type and mutant OriLyts.</p></sec><sec id="sec2dot7-viruses-17-00190"><title>2.7. Single Molecule Analysis of PF-8 Position and Area</title><p>Electron micrographs were converted from dm3 files to tiff files and analyzed for protein area and position of PF-8 using a Macro for ImageJ (NIH). Protein area was measured in pixels<sup>2</sup> using the elliptical selection tool and converted to nm<sup>2</sup>. The oligomeric states of PF-8 were subdivided into three different categories: &#x0003c;200 nm<sup>2</sup> (monomer/dimer), 200&#x02013;325 nm<sup>2</sup> (hexamer/dodecamer), and &#x0003e;325 nm<sup>2</sup> (&#x0003e;dodecamer). The cut-offs for the different oligomeric states were determined by looking at the distribution and/or groupings of the dot plots for PF-8&#x02032;s area under the different conditions while also considering the distribution pattern for GS (molecular standard).</p><p>The DNA position of PF-8 was determined by measuring the DNA length from the end of streptavidin to the beginning of PF-8 in pixels then that value was converted to nanometers and subsequently to base pairs. The conversion factor from pixels to nanometers was encoded in the dm3 files. The conversion factor of 2.9 bp/nm is based on the known distance between base pairs and nanometers [<xref rid="B27-viruses-17-00190" ref-type="bibr">27</xref>]. The frequency histograms have bin sizes set to 75 bp. Ultimately, 75 bp was chosen based on the diameter of PF-8 that was calculated from the area of PF-8, assuming a circular shape. Percentages of the quantification of different DNA and protein conformations were determined by totaling each conformation/phenotype from the three replicates and dividing it by the total number of DNA molecules counted in the three replicates and then multiplying by 100 for each DNA (OriLyt and mutant 1&#x02013;3). The calculated bend angles for induced protein binding to DNA were determined by using the angle tool in ImageJ to measure the opening angle and then subtracting that value from 180. The lines for measuring the opening angle were positioned so that they were approximately tangent to the DNA on opposite sides of the protein [<xref rid="B28-viruses-17-00190" ref-type="bibr">28</xref>]. The DNA bending angle was not calculated if the protein bound to the end of DNA or if protein binding induced a loop in the DNA. The protein area for the heat maps was subdivided into three groups: &#x0003e;325 nm<sup>2</sup>, 200&#x02013;325 nm<sup>2</sup>, and &#x0003c;200 nm<sup>2</sup> while the DNA sequence was grouped in bins of 75 bp.</p></sec><sec id="sec2dot8-viruses-17-00190"><title>2.8. Data Analysis and Statistics</title><p>Dot plots, frequency histograms, bar graphs, and heat maps were generated using GraphPad (Prism). Kruskal&#x02013;Wallis with Dunn&#x02019;s multiple comparison test was used to determine statistical significance for protein area, <xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Table S2</xref>. Images were compiled and annotated using Adobe Photoshop and Illustrator. Sequence-specific analysis for the OriLyt was performed with CLC Main Workbench (Qiagen). Models were generated using BioRender. Truncated PF-8 structures (PDB: 3HSL) were modeled with ChimeraX [<xref rid="B21-viruses-17-00190" ref-type="bibr">21</xref>,<xref rid="B29-viruses-17-00190" ref-type="bibr">29</xref>].</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-00190"><title>3. Results</title><sec id="sec3dot1-viruses-17-00190"><title>3.1. Purified PF-8 Forms Ring Structures In Vitro</title><p>DNA processivity factors are known to form a range of protein complexes [<xref rid="B1-viruses-17-00190" ref-type="bibr">1</xref>,<xref rid="B30-viruses-17-00190" ref-type="bibr">30</xref>]. For example, the eukaryotic sliding clamp forms a trimer, Herpesvirus simplex-1 forms a monomer, and EBV forms a dimer, tetramer, and possible larger complexes [<xref rid="B1-viruses-17-00190" ref-type="bibr">1</xref>,<xref rid="B30-viruses-17-00190" ref-type="bibr">30</xref>,<xref rid="B31-viruses-17-00190" ref-type="bibr">31</xref>,<xref rid="B32-viruses-17-00190" ref-type="bibr">32</xref>,<xref rid="B33-viruses-17-00190" ref-type="bibr">33</xref>]. With the differences in multimeric states observed among processivity factors, we sought to investigate the structure(s) PF-8 forms with a single molecule EM analysis and gel-based approaches. Using an imaging approach, we observed that PF-8 forms two distinct conformations: a petal-shaped structure that we hypothesize to be a tetramer and a ring-shaped structure we predict to be a hexamer (<xref rid="viruses-17-00190-f001" ref-type="fig">Figure 1</xref>A). In addition, both conformations contain a central pore (petal: 5.0 &#x000b1; 0.47 nm and ring: 6.1 &#x000b1; 0.89 nm) that is large enough to accommodate the width of the double helix of DNA; therefore, we hypothesize that PF-8 has the ability to encircle DNA (<xref rid="viruses-17-00190-f001" ref-type="fig">Figure 1</xref>B) [<xref rid="B34-viruses-17-00190" ref-type="bibr">34</xref>]. Gel analysis revealed a PF-8 band at approximately 52 kDa under denaturing conditions, which correlates with previous studies (<xref rid="viruses-17-00190-f001" ref-type="fig">Figure 1</xref>C) [<xref rid="B19-viruses-17-00190" ref-type="bibr">19</xref>,<xref rid="B35-viruses-17-00190" ref-type="bibr">35</xref>]. Based on the amino acid sequence of PF-8, the predicted monomeric weight is 42.4 kDa; therefore, the observed increase in molecular weight is likely due to protein post-translational modifications [<xref rid="B35-viruses-17-00190" ref-type="bibr">35</xref>,<xref rid="B36-viruses-17-00190" ref-type="bibr">36</xref>]. Glutamine synthetase (GS) which we used as a protein standard forms a ring-shaped structure with a central pore and has a similar monomeric weight (51.9 kDa) as PF-8 [<xref rid="B37-viruses-17-00190" ref-type="bibr">37</xref>,<xref rid="B38-viruses-17-00190" ref-type="bibr">38</xref>]. Next, we used a semi-native gel that contained a low amount of SDS to resolve the native folded state(s) of PF-8 and GS [<xref rid="B39-viruses-17-00190" ref-type="bibr">39</xref>]. The semi-native gel revealed a band present for GS around the size of the dodecamer, 12-mer (622.8 kDa), and a faint band around the predicted size of a hexamer (311.4 kDa, <xref rid="viruses-17-00190-f001" ref-type="fig">Figure 1</xref>D). GS in other species are known to form several oligomeric states; therefore, perhaps we are detecting less common oligomeric states that correspond to the bands present between the dodecamer and hexamer [<xref rid="B40-viruses-17-00190" ref-type="bibr">40</xref>]. Alternatively, bands in a native gel migrate not only based on size but also shape; therefore, it is a possibility that we are observing different protein orientations present in the gel [<xref rid="B41-viruses-17-00190" ref-type="bibr">41</xref>]. We consistently observed the PF-8 bands appeared as a W-shaped band, likely because PF-8 has a high pI value (8.9), which will impact the ability of the protein to enter and efficiently migrate in the gel [<xref rid="B42-viruses-17-00190" ref-type="bibr">42</xref>]. Nonetheless, the prominent band (between 480&#x02013;720 kDa) is comparable to the size of the GS dodecamer, and there is a faint band (between 146&#x02013;242 kDa) detected around the predicted size of a tetramer (denaturing gel PF-8 band molecular weight 52 kDa, 52 &#x000d7; 4 = 208 kDa). The results from the semi-native gel suggest that the ring-shaped structure present in the negative staining data could be two hexameric rings stacking on top of each other forming a dodecamer. Furthermore, the semi-native gel results indicate that the dodecamer band is present in greater abundance than the tetramer based on band intensity, which correlates with the ring-shaped structure (predicted dodecamer, n = 64), with negative staining being more frequently observed than the petal structure (predicted tetramer, n = 9). These results suggest that purified, full-length PF-8 can form a tetramer, hexamer, and/or dodecamer in the absence of DNA.</p><p>Next, we went on to explore how time and concentration influence the dynamics of PF-8&#x02032;s protein&#x02013;protein interactions involved in assembling higher oligomeric states. GS and PF-8 under varying times, concentrations, and temperatures were mounted onto glow-discharged, carbon-coated copper mesh grids, shadowed with evaporated tungsten, imaged, and analyzed. The electron micrographs revealed that GS predominantly forms a ring-like conformation with a central pore (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>A). When comparing the individual GS molecules in the micrographs to the known structure (PDB: 8PVG), GS primarily exhibits a top-down view that is present the majority of the time, and a side view that is less prevalent (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>B) [<xref rid="B43-viruses-17-00190" ref-type="bibr">43</xref>]. Previously, the top-down view was the most frequent conformation when GS was stained with uranyl acetate [<xref rid="B40-viruses-17-00190" ref-type="bibr">40</xref>]. PF-8 at the different incubation times mostly forms an annulus or ring-shaped conformation (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>C). <xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>D includes an electron micrograph and paired models of two ring-shaped structures assembling to form the dodecamer. Similar to GS, PF-8 forms a ring-shaped structure with a central pore and can display a similar side view. In addition, the formation of the hypothesized dodecamer state can be observed with two ring-shaped structures off-center from one another.</p><p>We compared the diameters and areas of GS and PF-8 (<xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Figure S1</xref>). Assuming a circular shape we used the measured area to calculate the diameters of PF-8 and GS prepared using tungsten rotary shadowing (<xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Figure S1A,B</xref>). The diameters of PF-8 and GS were 19.5 nm and 20.5 nm, respectively. The comparable diameter and area support PF-8 forming stacked hexamers (dodecamer). To approximate the number of monomers per ring structure visualized using negative staining, the area of the ring excluding the central DNA pore was divided by the measured area of a monomer (assuming a subunit of the petal-tetramer as a monomer, <xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Figure S1C,D</xref>). We estimated six monomers per ring. An important distinction in the methodologies is that sample preparation and staining impact measurements and cannot be compared across methods. These calculations provided independent verification of the PF-8 rings.</p><p>To alter the protein dynamics of PF-8, a relatively low concentration of PF-8 was incubated on ice (4 &#x000b0;C). We hypothesize that the population of proteins below &#x0003c;200 nm<sup>2</sup> represent monomeric/dimeric PF-8 (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>E, below dashed line) and tetramers, hexamers, or dodecamers, which were measured above 200 nm<sup>2</sup> (dashed line) but below 325 nm<sup>2</sup> (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>E, dotted line). Over three hours, we detected a measurable difference in median protein areas as well as an upward shift in the population in the dot plot (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>E). The values listed in <xref rid="viruses-17-00190-t001" ref-type="table">Table 1</xref> correlate to the dot plots depicted in <xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>E. <xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Table S2</xref> includes the statistical significance of all of the compared groups. Each dot represents the measured area of a single PF-8 protein. Protein concentration had a minimal impact on the median measured PF-8 area. Interestingly, we observed the greatest abundance of smaller proteins (&#x0003c;200 nm<sup>2</sup>) correlated with PF-8 incubated at 4 &#x000b0;C, the shortest duration (0.5 h), or lowest protein concertation (population below dashed line, <xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>E). Furthermore, the percentage of PF-8 monomers/dimers was greatest at 0.5 h (34.8% of total proteins measured), 100 ng (24.3%), and 4 &#x000b0;C (38.5%, <xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Figure S2A,C</xref>). All experimental variables examined displayed the hexamers/dodecamers population as the most abundant except PF-8 at 4 &#x000b0;C and the 3 h incubation time (<xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Figure S2A,C</xref>). As a molecular comparison, the distribution of the areas for GS showed multiple populations, validating our approach in detecting multiple-size protein complexes and/or different geometries (top-down or side) of a non-viral protein. Together, these results suggest time as a critical mediator of PF-8 higher-order oligomer formation (&#x0003e;325 nm<sup>2</sup>).</p></sec><sec id="sec3dot2-viruses-17-00190"><title>3.2. PF-8 DNA-Binding Affinity to Double-Stranded DNA via DNA Structural Specificity</title><p>Using our imaging-based approach, we visualized hundreds of individual DNA&#x02013;protein complexes, which we analyzed to determine PF-8&#x02019;s DNA binding position and the frequency of molecules bound to specific DNA locations. For our analysis, OriLyt was linearized and labeled with biotin and streptavidin (<xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>A,B, black arrowhead) and subsequently incubated with PF-8 in the absence (unfixed) and presence (fixed) of glutaraldehyde (<xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>A,B, white arrowhead). Glutaraldehyde helps stabilize the protein&#x02013;protein interactions by cross-linking amine groups [<xref rid="B44-viruses-17-00190" ref-type="bibr">44</xref>,<xref rid="B45-viruses-17-00190" ref-type="bibr">45</xref>]. Fractions from the size exclusion column of the DNA&#x02013;protein <italic toggle="yes">in vitro</italic> binding reaction were absorbed onto glow-discharged carbon-coated copper mesh grids, shadowed with tungsten, and visualized with TEM (<xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>A,B). Out of the 427 total positions measured for PF-8 bound to OriLyt under unfixed conditions 53.4% bound between 0 and 675 bp. In the absence of fixative, PF-8 bound to OriLyt between 525 and 600 bp (n = 37) at the highest frequency and regions 375-450 bp (n = 35), which correlates to three CAAT sites and 75&#x02013;150 bp (n = 32, <xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>C and <xref rid="viruses-17-00190-t002" ref-type="table">Table 2</xref>). While in the presence of glutaraldehyde, a comparable number of PF-8 molecules bound between 0 and 675 bp (51.8%, <xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>D). Out of the 361 total positions measured for PF-8 bound to the OriLyt under fixed conditions, the highest frequency was observed between 600 and 675 bp (n = 32), which corresponds to two CAAT sites and a TATA box. PF-8 also bound to DNA regions 450&#x02013;525 bp (n = 31), which correlates to a known AP-1 site and an AT-rich region and 375&#x02013;450 bp (n = 25), which encodes three CAAT sites (<xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>D and <xref rid="viruses-17-00190-t002" ref-type="table">Table 2</xref>). PF-8 may preferentially bind to certain CAAT, AP-1 sites, TATA boxes, and AT-rich regions. Another advantage of our approach is the capacity to detect both high and low-frequency binding sites, PF-8 mapped to DNA locations throughout the OriLyt, directly supporting PF-8&#x02019;s affinity to double-stranded DNA [<xref rid="B35-viruses-17-00190" ref-type="bibr">35</xref>]. To determine whether the PF-8 DNA peaks identified in our DNA mapping (<xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>D) indicate PF-8 sequence specific for known DNA consensus sequences (<xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Figure S3</xref>) [<xref rid="B10-viruses-17-00190" ref-type="bibr">10</xref>,<xref rid="B14-viruses-17-00190" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00190" ref-type="bibr">15</xref>], we introduced several nucleotide mutations (<xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Table S1</xref>) to OriLyt.</p><p>A subset of DNA-binding proteins will seek and bind to highly conserved DNA consensus sequences (base readout). For example, the transcription factor basic-helix-loop-helix protein Pho4 specifically binds to the E-box sequence within DNA [<xref rid="B46-viruses-17-00190" ref-type="bibr">46</xref>,<xref rid="B47-viruses-17-00190" ref-type="bibr">47</xref>]. While other DNA-binding proteins have an affinity to specific DNA structural features (shape readout) [<xref rid="B47-viruses-17-00190" ref-type="bibr">47</xref>,<xref rid="B48-viruses-17-00190" ref-type="bibr">48</xref>]. The HMG box protein is an example that predominately utilizes a shape readout [<xref rid="B47-viruses-17-00190" ref-type="bibr">47</xref>]. Shape readout refers to deviations in B-DNA that result in either a local or global 3D shape of the DNA helix. Local shape readout can include narrowing of the minor groove while global shape readout can include DNA bending; however, shape readouts are not limited to only those aspects [<xref rid="B49-viruses-17-00190" ref-type="bibr">49</xref>]. To determine which mechanism DNA-binding proteins utilize, mutations can be introduced in the DNA in order to alter local sequences or disrupt the local or global shape [<xref rid="B50-viruses-17-00190" ref-type="bibr">50</xref>]. Three mutant OriLyt DNAs were engineered to the preferential binding regions of PF-8. The two CAAT and TATA box motifs contained in the highest frequency peak under fixed conditions were mutated (underlined) from CAAT to C<underline>C</underline>AT and TATAAA to TA<underline>G</underline>AAA to generate Mutant 1 (M1). Mutant 2 (M2) was generated by mutating the three CAAT sites to C<underline>C</underline>AT between 375 and 450 bp, which was the third most frequent peak under fixed conditions. Mutant 3 (M3) had the combined mutations from both M1 and M2. PF-8 was separately incubated with each of the three mutant OriLyt DNAs, visualized with TEM, and analyzed (<xref rid="viruses-17-00190-f004" ref-type="fig">Figure 4</xref>A&#x02013;C). The frequency of PF-8 was mapped to the DNA binding position (gray bars), and the wild-type OriLyt PF-8 DNA binding frequencies are overlayed as open circles (<xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>B). The three highest frequency binding peaks PF-8 mapped to M1 were 375&#x02013;450 bp (n = 32), 450&#x02013;525 bp (n = 32), and 525&#x02013;600 bp (n = 25, <xref rid="viruses-17-00190-f004" ref-type="fig">Figure 4</xref>D). The peak that coincided with the mutated CAAT and TATA box motifs had a 2.6% decrease in PF-8 molecules binding to the region compared to the wild-type. The highest frequency peaks PF-8 mapped to M2 were 300&#x02013;375 bp (n = 30), 375&#x02013;450 bp (n = 29), and 525&#x02013;600 bp (n = 28, <xref rid="viruses-17-00190-f004" ref-type="fig">Figure 4</xref>E). The peak that contained the mutated motifs (375&#x02013;450 bp) had an increase of 1.3% of PF-8 molecules binding to the region compared to the wild-type. The three most frequent peaks mapped for M3 were 75&#x02013;150 bp (n = 32), 375&#x02013;450 bp (n = 24), and 600&#x02013;675 bp (n = 23) (<xref rid="viruses-17-00190-f004" ref-type="fig">Figure 4</xref>F). There was a 2.6% decrease in PF-8 binding observed between 600 and 675 bp compared to the wild-type, which was observed with M1. Between 375 and 450 bp, PF-8 had a 0.4% decrease in binding compared to the wild-type and a 1.7% decrease in binding compared to M2. The two highest peaks mapped for M3 correlated to two out of the three highest peaks for PF-8 under unfixed conditions. <xref rid="viruses-17-00190-t002" ref-type="table">Table 2</xref> summarizes the three primary peaks for PF-8 binding to the various DNAs under different conditions. Our mutagenesis approach revealed the prominence of a new peak (75&#x02013;150 bp) in M3. The mutant OriLyt DNA experiments suggest that DNA nucleotide substitutions may be altering the local or global DNA structure rather than the requirement for a base-specific or consensus sequence driving PF-8 binding. Evidence for a sequence-specific consensus sequence would have greatly diminished the protein binding to the location of mutations. Overall, the mutagenesis strategy successfully altered the PF-8 DNA-binding affinities.</p><p>In addition to the DNA positional analysis, we also quantified the protein area when PF-8 was bound to all DNA constructs (<xref rid="viruses-17-00190-f004" ref-type="fig">Figure 4</xref>G). We wanted to determine if association with DNA changed the measured PF-8 area and if fixation or DNA sequence influenced the protein&#x02013;protein interactions of PF-8. There is a measurable difference in the spread of the IQR between unfixed (215.2&#x02013;301.7 nm<sup>2</sup>) and fixed (243.2&#x02013;353.5 nm<sup>2</sup>) with an approximate 50nm<sup>2</sup> increase in IQR for the fixed group likely because of the absence of a crosslinking reagent reduces the stability of some of the larger protein complexes (<xref rid="viruses-17-00190-f004" ref-type="fig">Figure 4</xref>G and <xref rid="viruses-17-00190-t003" ref-type="table">Table 3</xref>). PF-8 under unfixed conditions had similar percentages of protein molecules &#x0003c;200 nm<sup>2</sup>, 200&#x02013;325 nm<sup>2</sup>, and &#x0003e;325 nm<sup>2</sup> compared to the two-hour time point in the absence of DNA, which is the approximate time it takes for the experimental setup of the DNA&#x02013;protein setup. There are similar distribution spreads and IQR in the protein area when comparing the fixed group to M1 and M2 suggesting similar PF-8 oligomeric states are interacting with these DNAs. M3 shows an IQR more similar to the unfixed group than the fixed indicating that the DNA mutations present in M3 OriLyt may be influencing the multimeric state of PF-8. Together the single molecular EM analysis revealed subtle changes in PF-8 DNA binding locations and protein areas.</p></sec><sec id="sec3dot3-viruses-17-00190"><title>3.3. PF-8 Protein Complexes Mediated Changes to OriLyt DNA Architectures</title><p>With our method, we are able to directly observe different conformations in DNA and protein. For example, we are able to detect if protein binding to DNA is producing multiple loops in the DNA or if protein conformations have uniform or distinct shapes and sizes (area). In order to quantify the OriLyt architecture and protein conformations, we unbiasedly scanned the EM grid and counted the different conformations and architecture present for each type of DNA. We verified that DNA binding did not modify the overall measured DNA length of OriLyt (<xref rid="app1-viruses-17-00190" ref-type="app">Supplementary Table S3</xref>). This additional analysis provides a comprehensive accounting of the different conformations present in protein-DNA binding reactions. <xref rid="viruses-17-00190-f005" ref-type="fig">Figure 5</xref>A&#x02013;C shows representative EM images of the different DNA and protein conformations: one complex, multiple complexes, and DNA without PF-8.</p><p>The EM micrograph montage includes a variety of examples of PF-8 OriLyt complexes we observed (<xref rid="viruses-17-00190-f005" ref-type="fig">Figure 5</xref>A,B). Representative images include a typical image that we would use to quantify the position and area of PF-8 (<xref rid="viruses-17-00190-f005" ref-type="fig">Figure 5</xref>A left and right panel). We also observed PF-8 binding at one of the ends of the DNA, with some of the end binding resulting in a loop. These PF-8 OriLyt complexes lacking streptavidin end-labeling were omitted from DNA position analysis due to the lack of reference point. PF-8 induced DNA-looping, which indicates that PF-8 is binding to the DNA at two different locations. It is possible that two ring-shaped hexamer complexes that have bound at different locations on the DNA are assembling into a stacked dodecamer (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>D). In addition, we observed two PF-8 complexes that were partially overlapping with one another (<xref rid="viruses-17-00190-f005" ref-type="fig">Figure 5</xref>B). Furthermore, the central pores formed in the petal and ring-shaped structures are both wide enough to accommodate two segments of DNA to pass through (<xref rid="viruses-17-00190-f001" ref-type="fig">Figure 1</xref>C), supporting the PF-8 ring complex structure. We observed a decrease in the one protein complex binding with the mutant DNAs compared to the wild-type and an increase in the presence of the two PF-8 complexes (<xref rid="viruses-17-00190-f005" ref-type="fig">Figure 5</xref>D). The most prominent peak for PF-8-induced bending in the OriLyt was between 30 and 40&#x000b0; (<xref rid="viruses-17-00190-f005" ref-type="fig">Figure 5</xref>E). The eukaryotic processivity factor proliferating cell nuclear antigen (PCNA) encircles the DNA and is known to induce a 40&#x000b0; bend in DNA; thus, PF-8 is perhaps behaving in a similar manner, encircling OriLyt DNA [<xref rid="B30-viruses-17-00190" ref-type="bibr">30</xref>].</p></sec><sec id="sec3dot4-viruses-17-00190"><title>3.4. Multivariable Analysis of PF-8 Protein Area and DNA Binding Position</title><p>Various DNA-binding proteins can bind to specific sequences when assembled into larger protein complexes [<xref rid="B51-viruses-17-00190" ref-type="bibr">51</xref>,<xref rid="B52-viruses-17-00190" ref-type="bibr">52</xref>]. For example, the monomer of protelomerase TelK binds to DNA non-specifically while the dimers bind to a target-specific sequence [<xref rid="B52-viruses-17-00190" ref-type="bibr">52</xref>]. In addition, we have previously shown that RTA dimers specifically bind to AT-rich and AP-1 sites within the OriLyt [<xref rid="B22-viruses-17-00190" ref-type="bibr">22</xref>]. We aimed to determine if certain oligomeric states of PF-8 localize to specific locations on the DNA. In order to answer that question, we constructed heat maps that consist of three variables: binding position, protein area, and frequency. For unfixed conditions, the PF-8 hexamer/dodecamer was the most prevalent at 375&#x02013;450 bp, 525&#x02013;600 bp, and 75&#x02013;150 bp, which correlates with the three most frequent peaks in the histogram (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>A top). The two highest frequency spots for PF-8 under fixed conditions are 600&#x02013;675 bp and 450&#x02013;525 bp with an oligomeric state of a hexamer/dodecamer (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>A bottom). The two most frequent locations for mutant 1 were 375&#x02013;450 bp and 525&#x02013;600 bp with an oligomeric state greater than a dodecamer (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>B). Mutant 2 revealed that PF-8 preferentially binds to 300&#x02013;375 bp and 525&#x02013;600 bp greater than a dodecamer state (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>C). PF-8 binds to mutant 3 with a strong preference at 75&#x02013;150 bp as a dodecamer/hexamer (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>D). The monomer/dimer population of PF-8 binds non-specifically throughout the length of OriLyt. At least 45% of the PF-8 molecules bound to OriLyt are hexamer/dodecamer (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>E). There is a decrease in the number of molecules greater than dodecamer and an increase in the monomer/dimer population in the unfixed group compared to the fixed. We observed an increase in the greater-than-dodecamer population for mutants 1 and 2. Mutant 3 had the largest percentage of PF-8 molecules in the monomer/dimer range. PF-8 monomer/dimers are less frequently bound to DNA, and their binding appears general throughout the DNA, while ring structures or multiple ring complexes localize to discrete locations. Fixation stabilizes the multiple ring complexes (&#x0003e;dodecamer) bound to DNA. We predict that PF-8 hexameric rings are more likely to bind wild-type OriLyt. This could indicate that monomers initially bind and that the subsequent protein&#x02013;protein interactions are enhanced by PF-8 binding to DNA (by restricting movement and increasing the probability of protein&#x02013;protein interactions) in order to promote the ring complexes. Alternatively, ring formation could occur prior to proteins interacting with DNA; however, the PF-8 ring affinity to OriLyt is greater than monomers, which enhances hexamer/dodecamer rings bound to DNA.</p><p><xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>F highlights the highest frequency box observed in the heatmaps (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>A&#x02013;D, yellow boxes) for wild-type and mutant OriLyts under fixed conditions. The most abundant area PF-8 bound to two distinct locations on the wild-type OriLyt were in the dodecamer/hexamer range (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>F, black dots). PF-8 bound to mutant 1 OriLyt showed shifted binding preference away from mutant 1 location (600&#x02013;675 bp) to two new upstream locations and had increased protein areas (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>F, top dark grey dots). PF-8 bound to mutant 2 OriLyt also showed shifted binding preference; however, this occurred both upstream and downstream of the mutant 2 location (375&#x02013;450 bp). Similar to PF-8 bound to mutant 1, PF-8 bound to mutant 2 also increased protein area into the &#x0003e;dodecamer range (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>F, grey dots). Finally, PF-8 bound to mutant 3 OriLyt, which possesses both mutant 1 and mutant 2 mutations, revealed that PF-8 dramatically shifted upstream closer to the biotin/streptavidin labeled end of the DNA. The observed protein area and DNA location shift we captured when comparing the four different OriLyt fragments revealed the dynamic DNA binding activity of PF-8. These data also support PF-8 area and DNA binding is influenced by DNA sequence and/or shape.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00190"><title>4. Discussion</title><p>We utilized a single-molecule approach with TEM to characterize PF-8 protein&#x02013;protein and DNA&#x02013;protein interactions. The advantage of this technique over more traditional gel-based assays is that heterogenous populations can be observed and individual populations can be subdivided and further analyzed. While more traditional gel-based assays provide a bulk analysis and reveal the most prominent species. Additionally, a direct imaging approach provides both quantitative and qualitative data which when compiled together allows for a comprehensive characterization. We investigated the oligomeric state of PF-8 and PF-8 bound to KSHV lytic origin DNA. In addition, we mapped the binding frequency of PF-8 to the wild-type KSHV OriLyt and three mutant OriLyts. Furthermore, we quantified the different DNA architectures and protein phenotypes among the wild-type OriLyt and three mutant OriLyts.</p><p>Most studies suggest that PF-8 forms a dimer in solution and when bound to DNA, with a few studies suggesting a tetramer state [<xref rid="B19-viruses-17-00190" ref-type="bibr">19</xref>,<xref rid="B53-viruses-17-00190" ref-type="bibr">53</xref>]. No studies have investigated the oligomeric state of full-length PF-8 at the single-molecule level. The crystal structure of a truncated PF-8 lacking the C-terminus revealed that it can form a dimer when unbound to DNA. EBV&#x02019;s processivity factor BMRF1 is known to form dimers and tetramers based on a truncated crystal structure [<xref rid="B31-viruses-17-00190" ref-type="bibr">31</xref>,<xref rid="B32-viruses-17-00190" ref-type="bibr">32</xref>]. In addition, ring-shaped structures with a central pore were observed when BMRF1 was stained with uranyl acetate and were hypothesized to be a hexamer. The central pore and complex measurements (pore: 5.3 &#x000b1; 0.8 nm complex: 15.5 &#x000b1; 0.8 nm) were similar to PF-8 (<xref rid="viruses-17-00190-t004" ref-type="table">Table 4</xref>) [<xref rid="B33-viruses-17-00190" ref-type="bibr">33</xref>]. Based on the denaturing gel, semi-native gel, and tungsten rotary shadowing data, PF-8 may form a similar oligomeric state as GS. GS is known to form a dodecamer through the stacking of two hexamers on top of each other with a central pore in the center [<xref rid="B54-viruses-17-00190" ref-type="bibr">54</xref>]. The top-down view is likely the most prominent conformation, which is similar to GS, suggesting more of a hexamer formation as opposed to the addition of a side view, which suggests a dodecamer state through the stacking of two hexamer rings. Since the central pore is large enough to accommodate the double helix of DNA, we hypothesize that the PF-8 is encircling the DNA. Some processivity factors such as PCNA are known to have a central pore that DNA can pass through [<xref rid="B30-viruses-17-00190" ref-type="bibr">30</xref>]. The formation of a hexamer and/or dodecamer state could be a unique characteristic among gamma herpesviruses processivity factors; specifically, a ring conformation that encircles DNA, leading to DNA bending at a certain angle. Several processivity factors that encircle DNA are known to cause DNA bending angles similar to our observed results, adding further support to our hypothesis [<xref rid="B30-viruses-17-00190" ref-type="bibr">30</xref>].</p><p>Although PF-8 is required for the efficient replication of the KSHV genome, it is not the only protein capable of binding to OriLyt DNA. RTA and DNA polymerase are both lytic KSHV replication proteins that are known to interact with PF-8 and bind to DNA [<xref rid="B13-viruses-17-00190" ref-type="bibr">13</xref>,<xref rid="B26-viruses-17-00190" ref-type="bibr">26</xref>]. Rossetto et al. showed that PF-8 binding to the CAAT palindromes was enhanced with the presence of RTA using a ChIP assay with PCR primers flanking the CAAT palindrome region [<xref rid="B26-viruses-17-00190" ref-type="bibr">26</xref>]. The addition of other proteins that interact with PF-8 may alter the sequence-specific region that PF-8 binds. In addition, our method utilizing TEM allows for several populations to be studied, while ChIP coupled with PCR can only indicate whether a protein is binding to a particular region. It does not provide information on the frequency or if the protein is binding to other regions at a higher frequency. Furthermore, PF-8 could bind to those regions and wait for the other proteins to associate with the DNA so that DNA replication can be initiated. C/EBP proteins are transcription factors that are known to bind to CAAT sequences [<xref rid="B55-viruses-17-00190" ref-type="bibr">55</xref>]. C/EBP proteins have been previously shown to associate with other proteins that are known to be involved in lytic DNA replication, such as K8 and RTA [<xref rid="B56-viruses-17-00190" ref-type="bibr">56</xref>,<xref rid="B57-viruses-17-00190" ref-type="bibr">57</xref>]. PF-8 could be dwelling in this area while other proteins are recruited to the area to form the pre-initiation DNA replication complex that requires RTA and K8 [<xref rid="B58-viruses-17-00190" ref-type="bibr">58</xref>].</p><p>During protein&#x02013;DNA binding, PF-8 scans the OriLyt sequence for distinct DNA shape readouts. PF-8 rings are more likely bound to 1-675 bp region and eventually settle into specific regions. Introducing DNA mutations modified PF-8 binding locations as well as PF-8-measured areas (<xref rid="viruses-17-00190-f006" ref-type="fig">Figure 6</xref>F). The presence of mutant 1 nucleotide substitutions enhanced the accumulation of PF-8 complexes with greater areas to localize more upstream proximal to the wild-type OriLyt hexameric rings. PF-8 bound to mutant 2 shifted the PF-8 into the higher area category (above the dotted line) and shifted binding upstream and downstream of the mutation site. The accumulation of all six mutations (mutant 1 plus mutant 2) resulted in an upstream shift of hexameric PF-8 rings (between dashed and dotted lines) to localize to the 75&#x02013;150 bp region. Future studies will aim to decipher the shape readouts, specifically the contributions of GC- and AT-composition, major and minor groove frequency, and span additional structural features known to impact protein&#x02013;DNA-binding affinities [<xref rid="B49-viruses-17-00190" ref-type="bibr">49</xref>].</p><p>Taken together, our findings add key insights into explaining PF-8 activity in the context of the infectious cycle. During the lytic phase, PF-8 is first translated in the cytoplasm, forms mostly monomers and dimers, and, subsequently, localizes to the nucleus, which is the site of viral DNA replication (<xref rid="viruses-17-00190-f007" ref-type="fig">Figure 7</xref>A). As the lytic cycle progresses, the concentration of PF-8 in the cytoplasm decreases and increases in the nucleus. Furthermore, the volume of the nucleus is much less compared to the cytoplasm, further increasing the effective concentration of PF-8 in the nucleus. The effective concentration of PF-8 may need to be at a high level to promote the higher oligomeric states to be achieved (<xref rid="viruses-17-00190-f002" ref-type="fig">Figure 2</xref>E). In addition, those higher oligomeric states may be needed for PF-8 to preferentially bind to specific regions within the OriLyt for processivity function and efficient lytic DNA replication. The dimerization domains (orange) and KSHV DNA polymerase (purple) of PF-8 are pseudo colored on space filling model of an <italic toggle="yes">E. coli</italic> purified PF-8 (PDB:3HSL, <xref rid="viruses-17-00190-f007" ref-type="fig">Figure 7</xref>B,C) overlap. PF-8 monomers/dimers in the cytoplasm would bind KSHV POL and translocate the POL into the nucleus. KSHV POL lacks its own nuclear localization sequence and requires PF-8 binding to enter the nucleus [<xref rid="B59-viruses-17-00190" ref-type="bibr">59</xref>]. PF-8 dimers would contain two DNA POL binding sites and enhance POL nuclear localization. Within the nucleus, we believe three dimers oligomerize to form hexameric rings. The location of the DNA binding domains supports our model where the viral DNA is threaded through the central pore and a greater number of PF-8 proteins in a ring confirmation would encode more DNA-binding sites compared to monomers or dimers.</p><p>Our approach to characterizing PF-8 at the single molecule utilizes an <italic toggle="yes">in vitro</italic> system with purified components. A limitation of using an <italic toggle="yes">in vitro</italic> approach is that the system lacks cellular or other viral components that may influence DNA binding or protein&#x02013;protein interactions. Studying the individual components of lytic DNA replication can help provide a basis or initial understanding of how these components behave by themselves and may help guide <italic toggle="yes">in vivo</italic> or cellular studies. Future studies include performing a combinational analysis of PF-8 with other lytic DNA replication proteins that interact with PF-8 such as RTA or DNA polymerase.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Jack Griffith and Smaranda Wilcox for their expert advice, and the past and present members of the Costantini laboratory for scientific discussions. We dedicate this work to Roger Eibest for generously donating time and technical expertise to maintain the transmission electron microscope.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-17-00190"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/v17020190/s1">https://www.mdpi.com/article/10.3390/v17020190/s1</uri>, Figure S1: Area measurements and diameter calculations for PF-8 and GS; Figure S2: Proportion of the different multimeric states of PF-8 in the absence of DNA; Figure S3: Annotated OriLyt sequence; Table S1: OriLyt site-directed mutagenesis primers; Table S2: Statistical significance of protein areas in the absence of DNA; Table S3: OriLyt DNA full-length measurements.</p><supplementary-material id="viruses-17-00190-s001" position="float" content-type="local-data"><media xlink:href="viruses-17-00190-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, L.M.C. and J.K.T.; methodology, L.M.C., J.K.T. and M.M.; software, J.K.T.; validation, L.M.C., J.K.T. and M.M.; formal analysis, L.M.C. and J.K.T.; investigation, L.M.C., J.K.T. and M.M.; resources, L.M.C.; data curation, L.M.C. and J.K.T.; writing&#x02014;original draft preparation, L.M.C. and J.K.T.; writing&#x02014;review and editing, L.M.C., J.K.T. and M.M.; visualization, L.M.C. and J.K.T.; supervision, L.M.C.; project administration, L.M.C.; funding acquisition, L.M.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">KSHV</td><td align="left" valign="middle" rowspan="1" colspan="1">Kaposi&#x02019;s Sarcoma Herpesvirus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PF-8</td><td align="left" valign="middle" rowspan="1" colspan="1">Processivity Factor-8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">POL</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA polymerase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OriLyt</td><td align="left" valign="middle" rowspan="1" colspan="1">Origin of replication</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EBV</td><td align="left" valign="middle" rowspan="1" colspan="1">Epstein&#x02013;Barr Virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KS</td><td align="left" valign="middle" rowspan="1" colspan="1">Kaposi Sarcoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ORF</td><td align="left" valign="middle" rowspan="1" colspan="1">Open reading frame</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RRE</td><td align="left" valign="middle" rowspan="1" colspan="1">RTA response element</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEM</td><td align="left" valign="middle" rowspan="1" colspan="1">Transmission electron microscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GS</td><td align="left" valign="middle" rowspan="1" colspan="1">Glutamine synthetase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">M1-3</td><td align="left" valign="middle" rowspan="1" colspan="1">Mutant 1, Mutant 2, or Mutant 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">nm</td><td align="left" valign="middle" rowspan="1" colspan="1">nanometers</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ng</td><td align="left" valign="middle" rowspan="1" colspan="1">nanograms</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-viruses-17-00190"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cohan</surname><given-names>B.</given-names></name>
<name><surname>Frappier</surname><given-names>L.</given-names></name>
</person-group><article-title>Herpesvirus DNA Polymerase Processivity Factors: Not Just for DNA Synthesis</article-title><source>Virus Res.</source><year>2021</year><volume>298</volume><fpage>198394</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2021.198394</pub-id><pub-id pub-id-type="pmid">33775751</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00190"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Lint</surname><given-names>A.L.</given-names></name>
<name><surname>Knipe</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Herpesviruses</article-title><source>Encycl. Microbiol.</source><year>2019</year><fpage>565</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-801238-3.02509-5</pub-id></element-citation></ref><ref id="B3-viruses-17-00190"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Bai</surname><given-names>L.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>R.</given-names></name>
<name><surname>Lan</surname><given-names>K.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology</article-title><source>Infectious Agents Associated Cancers: Epidemiology and Molecular Biology Advances in Experimental Medicine and Biology</source><person-group person-group-type="editor">
<name><surname>Cai</surname><given-names>Q.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Lan</surname><given-names>K.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Singapore</publisher-loc><year>2017</year><volume>1018</volume><fpage>91</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/978-981-10-5765-6_7</pub-id></element-citation></ref><ref id="B4-viruses-17-00190"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naimo</surname><given-names>E.</given-names></name>
<name><surname>Zischke</surname><given-names>J.</given-names></name>
<name><surname>Schulz</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Recent Advances in Developing Treatments of Kaposi&#x02019;s Sarcoma Herpesvirus-Related Diseases</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1797</elocation-id><pub-id pub-id-type="doi">10.3390/v13091797</pub-id><pub-id pub-id-type="pmid">34578378</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00190"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polizzotto</surname><given-names>M.N.</given-names></name>
<name><surname>Uldrick</surname><given-names>T.S.</given-names></name>
<name><surname>Hu</surname><given-names>D.</given-names></name>
<name><surname>Yarchoan</surname><given-names>R.</given-names></name>
</person-group><article-title>Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome</article-title><source>Front. Microbiol.</source><year>2012</year><volume>3</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2012.00073</pub-id><pub-id pub-id-type="pmid">22403576</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00190"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Myoung</surname><given-names>J.</given-names></name>
<name><surname>Ganem</surname><given-names>D.</given-names></name>
</person-group><article-title>Generation of a Doxycycline-Inducible KSHV Producer Cell Line of Endothelial Origin: Maintenance of Tight Latency with Efficient Reactivation upon Induction</article-title><source>J. Virol. Methods</source><year>2011</year><volume>174</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2011.03.012</pub-id><pub-id pub-id-type="pmid">21419799</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00190"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minhas</surname><given-names>V.</given-names></name>
<name><surname>Wood</surname><given-names>C.</given-names></name>
</person-group><article-title>Epidemiology and Transmission of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>4178</fpage><lpage>4194</lpage><pub-id pub-id-type="doi">10.3390/v6114178</pub-id><pub-id pub-id-type="pmid">25375883</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00190"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Schulz</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus-Antiviral Treatment</article-title><source>New Drug Development for Known and Emerging Viruses</source><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2021</year><fpage>191</fpage><lpage>227</lpage><isbn>9783527810697</isbn></element-citation></ref><ref id="B9-viruses-17-00190"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coen</surname><given-names>N.</given-names></name>
<name><surname>Duraffour</surname><given-names>S.</given-names></name>
<name><surname>Snoeck</surname><given-names>R.</given-names></name>
<name><surname>Andrei</surname><given-names>G.</given-names></name>
</person-group><article-title>KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>4731</fpage><lpage>4759</lpage><pub-id pub-id-type="doi">10.3390/v6114731</pub-id><pub-id pub-id-type="pmid">25421895</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00190"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Chan</surname><given-names>M.Y.</given-names></name>
<name><surname>Zhu</surname><given-names>F.X.</given-names></name>
<name><surname>Lukac</surname><given-names>D.M.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus Ori&#x02014;Lyt -Dependent DNA Replication: Cis -Acting Requirements for Replication and Ori&#x02014;Lyt -Associated RNA Transcription</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>8615</fpage><lpage>8629</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.16.8615-8629.2004</pub-id><pub-id pub-id-type="pmid">15280471</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00190"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>Q.</given-names></name>
<name><surname>Verma</surname><given-names>S.C.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Robertson</surname><given-names>E.S.</given-names></name>
</person-group><article-title>Molecular Biology of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus and Related Oncogenesis</article-title><source>Adv. Virus Res.</source><year>2010</year><volume>78</volume><fpage>87</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-385032-4.00003-3</pub-id><pub-id pub-id-type="pmid">21040832</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00190"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Liao</surname><given-names>Q.</given-names></name>
<name><surname>Ricciardi</surname><given-names>R.P.</given-names></name>
<name><surname>Peng</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus Processivity Factor-8 Dimerizes in Cytoplasm before Being Translocated to Nucleus</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2010</year><volume>397</volume><fpage>520</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.05.147</pub-id><pub-id pub-id-type="pmid">20515658</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00190"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L.-W.</given-names></name>
<name><surname>Wang</surname><given-names>S.-S.</given-names></name>
<name><surname>Chen</surname><given-names>L.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>H.-Y.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Hung</surname><given-names>C.-H.</given-names></name>
<name><surname>Lin</surname><given-names>C.-L.</given-names></name>
<name><surname>Chang</surname><given-names>P.-J.</given-names></name>
</person-group><article-title>Interaction and Assembly of the DNA Replication Core Proteins of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus</article-title><source>Microbiol. Spectr.</source><year>2023</year><volume>11</volume><elocation-id>e0225423</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.02254-23</pub-id><pub-id pub-id-type="pmid">37874136</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00190"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aucoin</surname><given-names>D.P.</given-names></name>
<name><surname>Colletti</surname><given-names>K.S.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Cei</surname><given-names>S.A.</given-names></name>
<name><surname>Pari</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Contains Two Functional Lytic Origins of DNA Replication</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>7890</fpage><lpage>7896</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.15.7890-7896.2002</pub-id><pub-id pub-id-type="pmid">12097603</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00190"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>C.L.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>F.X.</given-names></name>
<name><surname>Kudchodkar</surname><given-names>S.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus Lytic Origin (Ori-Lyt)-Dependent DNA Replication: Identification of the Ori-Lyt and Association of K8 BZip Protein with the Origin</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>5578</fpage><lpage>5588</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.10.5578-5588.2003</pub-id><pub-id pub-id-type="pmid">12719550</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00190"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aneja</surname><given-names>K.K.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Reactivation and Lytic Replication of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus: An Update</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><elocation-id>613</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.00613</pub-id><pub-id pub-id-type="pmid">28473805</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00190"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>K.</given-names></name>
<name><surname>Dai</surname><given-names>C.Y.</given-names></name>
<name><surname>Ricciardi</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Cloning and Functional Analysis of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus DNA Polymerase and Its Processivity Factor</article-title><source>J. Virol.</source><year>1998</year><volume>72</volume><fpage>6228</fpage><lpage>6232</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.7.6228-6232.1998</pub-id><pub-id pub-id-type="pmid">9621095</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00190"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Purushothaman</surname><given-names>P.</given-names></name>
<name><surname>Dabral</surname><given-names>P.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Sarkar</surname><given-names>R.</given-names></name>
<name><surname>Verma</surname><given-names>S.C.</given-names></name>
</person-group><article-title>KSHV Genome Replication and Maintenance</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.00054</pub-id><pub-id pub-id-type="pmid">26870016</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00190"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gutierrez</surname><given-names>I.V.</given-names></name>
<name><surname>Sarkar</surname><given-names>P.</given-names></name>
<name><surname>Rossetto</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus Processivity Factor, ORF59, Binds to Canonical and Linker Histones, and Its Carboxy Terminus Is Dispensable for Viral DNA Synthesis</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><elocation-id>e02169-20</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.02169-20</pub-id><pub-id pub-id-type="pmid">33361421</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00190"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Travis</surname><given-names>J.K.</given-names></name>
<name><surname>Costantini</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Inhibiting KSHV Replication by Targeting the Essential Activities of KSHV Processivity Protein, PF-8</article-title><source>J. Med. Virol.</source><year>2024</year><volume>96</volume><fpage>e29958</fpage><pub-id pub-id-type="doi">10.1002/jmv.29958</pub-id><pub-id pub-id-type="pmid">39370884</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00190"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baltz</surname><given-names>J.L.</given-names></name>
<name><surname>Filman</surname><given-names>D.J.</given-names></name>
<name><surname>Ciustea</surname><given-names>M.</given-names></name>
<name><surname>Silverman</surname><given-names>J.E.Y.</given-names></name>
<name><surname>Lautenschlager</surname><given-names>C.L.</given-names></name>
<name><surname>Coen</surname><given-names>D.M.</given-names></name>
<name><surname>Ricciardi</surname><given-names>R.P.</given-names></name>
<name><surname>Hogle</surname><given-names>J.M.</given-names></name>
</person-group><article-title>The Crystal Structure of PF-8, the DNA Polymerase Accessory Subunit from Kaposi&#x02019;s Sarcoma-Associated Herpesvirus</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>12215</fpage><lpage>12228</lpage><pub-id pub-id-type="doi">10.1128/JVI.01158-09</pub-id><pub-id pub-id-type="pmid">19759157</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00190"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calhoun</surname><given-names>J.C.</given-names></name>
<name><surname>Damania</surname><given-names>B.</given-names></name>
<name><surname>Griffith</surname><given-names>J.D.</given-names></name>
<name><surname>Costantini</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Electron Microscopy Mapping of the DNA-Binding Sites of Monomeric, Dimeric, and Multimeric KSHV RTA Protein</article-title><source>J. Virol.</source><year>2023</year><volume>97</volume><fpage>e0063723</fpage><pub-id pub-id-type="doi">10.1128/jvi.00637-23</pub-id><pub-id pub-id-type="pmid">37750723</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00190"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Arthur</surname><given-names>C.P.</given-names></name>
<name><surname>Ciferri</surname><given-names>C.</given-names></name>
</person-group><article-title>High-Throughput Protein Analysis Using Negative Stain Electron Microscopy and 2D Classification</article-title><source>Methods in Molecular Biology</source><publisher-name>Humana Press Inc.</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2019</year><volume>Volume 2025</volume><fpage>477</fpage><lpage>485</lpage></element-citation></ref><ref id="B24-viruses-17-00190"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsutakawa</surname><given-names>S.E.</given-names></name>
<name><surname>Sarker</surname><given-names>A.H.</given-names></name>
<name><surname>Ng</surname><given-names>C.</given-names></name>
<name><surname>Arvai</surname><given-names>A.S.</given-names></name>
<name><surname>Shin</surname><given-names>D.S.</given-names></name>
<name><surname>Shih</surname><given-names>B.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Thwin</surname><given-names>A.C.</given-names></name>
<name><surname>Tsai</surname><given-names>M.-S.</given-names></name>
<name><surname>Willcox</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Human XPG Nuclease Structure, Assembly, and Activities with Insights for Neurodegeneration and Cancer from Pathogenic Mutations</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>14127</fpage><lpage>14138</lpage><pub-id pub-id-type="doi">10.1073/pnas.1921311117</pub-id><pub-id pub-id-type="pmid">32522879</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00190"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDowell</surname><given-names>M.E.</given-names></name>
<name><surname>Purushothaman</surname><given-names>P.</given-names></name>
<name><surname>Rossetto</surname><given-names>C.C.</given-names></name>
<name><surname>Pari</surname><given-names>G.S.</given-names></name>
<name><surname>Verma</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Phosphorylation of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus Processivity Factor ORF59 by a Viral Kinase Modulates Its Ability To Associate with RTA and Ori Lyt</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>8038</fpage><lpage>8052</lpage><pub-id pub-id-type="doi">10.1128/JVI.03460-12</pub-id><pub-id pub-id-type="pmid">23678174</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00190"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossetto</surname><given-names>C.C.</given-names></name>
<name><surname>Susilarini</surname><given-names>N.K.</given-names></name>
<name><surname>Pari</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Interaction of Kaposi&#x02019;s Sarcoma-Associated Herpesvirus ORF59 with OriLyt Is Dependent on Binding with K-Rta</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>3833</fpage><lpage>3841</lpage><pub-id pub-id-type="doi">10.1128/JVI.02361-10</pub-id><pub-id pub-id-type="pmid">21289111</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00190"><label>27.</label><element-citation publication-type="webpage"><article-title>DNA Packaging: Nucleosomes and Chromatin|Learn Science at Scitable</article-title><comment>Available online: <ext-link xlink:href="https://www.nature.com/scitable/topicpage/dna-packaging-nucleosomes-and-chromatin-310/" ext-link-type="uri">https://www.nature.com/scitable/topicpage/dna-packaging-nucleosomes-and-chromatin-310/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-16">(accessed on 16 June 2024)</date-in-citation></element-citation></ref><ref id="B28-viruses-17-00190"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beckwitt</surname><given-names>E.C.</given-names></name>
<name><surname>Kong</surname><given-names>M.</given-names></name>
<name><surname>Van Houten</surname><given-names>B.</given-names></name>
</person-group><article-title>Studying Protein-DNA Interactions Using Atomic Force Microscopy</article-title><source>Semin. Cell Dev. Biol.</source><year>2018</year><volume>73</volume><fpage>220</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2017.06.028</pub-id><pub-id pub-id-type="pmid">28673677</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00190"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pettersen</surname><given-names>E.F.</given-names></name>
<name><surname>Goddard</surname><given-names>T.D.</given-names></name>
<name><surname>Huang</surname><given-names>C.C.</given-names></name>
<name><surname>Meng</surname><given-names>E.C.</given-names></name>
<name><surname>Couch</surname><given-names>G.S.</given-names></name>
<name><surname>Croll</surname><given-names>T.I.</given-names></name>
<name><surname>Morris</surname><given-names>J.H.</given-names></name>
<name><surname>Ferrin</surname><given-names>T.E.</given-names></name>
</person-group><article-title>UCSF ChimeraX: Structure Visualization for Researchers, Educators, and Developers</article-title><source>Protein Sci.</source><year>2021</year><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00190"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dieckman</surname><given-names>L.M.</given-names></name>
<name><surname>Freudenthal</surname><given-names>B.D.</given-names></name>
<name><surname>Todd Washington</surname><given-names>M.</given-names></name>
</person-group><article-title>PCNA Structure and Function: Insights from Structures of PCNA Complexes and Post-Translationally Modified PCNA</article-title><source>Subcell. Biochem.</source><year>2012</year><volume>62</volume><fpage>281</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1007/978-94-007-4572-8_15</pub-id><pub-id pub-id-type="pmid">22918591</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00190"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murayama</surname><given-names>K.</given-names></name>
<name><surname>Nakayama</surname><given-names>S.</given-names></name>
<name><surname>Kato-Murayama</surname><given-names>M.</given-names></name>
<name><surname>Akasaka</surname><given-names>R.</given-names></name>
<name><surname>Ohbayashi</surname><given-names>N.</given-names></name>
<name><surname>Kamewari-Hayami</surname><given-names>Y.</given-names></name>
<name><surname>Terada</surname><given-names>T.</given-names></name>
<name><surname>Shirouzu</surname><given-names>M.</given-names></name>
<name><surname>Tsurumi</surname><given-names>T.</given-names></name>
<name><surname>Yokoyama</surname><given-names>S.</given-names></name>
</person-group><article-title>Crystal Structure of Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>35896</fpage><lpage>35905</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.051581</pub-id><pub-id pub-id-type="pmid">19801550</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00190"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakayama</surname><given-names>S.</given-names></name>
<name><surname>Murata</surname><given-names>T.</given-names></name>
<name><surname>Yasui</surname><given-names>Y.</given-names></name>
<name><surname>Murayama</surname><given-names>K.</given-names></name>
<name><surname>Isomura</surname><given-names>H.</given-names></name>
<name><surname>Kanda</surname><given-names>T.</given-names></name>
<name><surname>Tsurumi</surname><given-names>T.</given-names></name>
</person-group><article-title>Tetrameric Ring Formation of Epstein-Barr Virus Polymerase Processivity Factor Is Crucial for Viral Replication</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>12589</fpage><lpage>12598</lpage><pub-id pub-id-type="doi">10.1128/JVI.01394-10</pub-id><pub-id pub-id-type="pmid">20926567</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00190"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makhov</surname><given-names>A.M.</given-names></name>
<name><surname>Subramanian</surname><given-names>D.</given-names></name>
<name><surname>Holley-Guthrie</surname><given-names>E.</given-names></name>
<name><surname>Kenney</surname><given-names>S.C.</given-names></name>
<name><surname>Griffith</surname><given-names>J.D.</given-names></name>
</person-group><article-title>The Epstein-Barr Virus Polymerase Accessory Factor BMRF1 Adopts a Ring-Shaped Structure as Visualized by Electron Microscopy</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>40358</fpage><lpage>40361</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408733200</pub-id><pub-id pub-id-type="pmid">15286084</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00190"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serec</surname><given-names>K.</given-names></name>
<name><surname>&#x00160;egedin</surname><given-names>N.</given-names></name>
<name><surname>Kraja&#x0010d;i&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Babi&#x00107;</surname><given-names>S.D.</given-names></name>
</person-group><article-title>Conformational Transitions of Double-Stranded Dna in Thin Films</article-title><source>Appl. Sci.</source><year>2021</year><volume>11</volume><elocation-id>2360</elocation-id><pub-id pub-id-type="doi">10.3390/app11052360</pub-id></element-citation></ref><ref id="B35-viruses-17-00190"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruby Chan</surname><given-names>S.</given-names></name>
<name><surname>Chandran</surname><given-names>B.</given-names></name>
</person-group><article-title>Characterization of Human Herpesvirus 8 ORF59 Protein (PF-8) and Mapping of the Processivity and Viral DNA Polymerase-Interacting Domains</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>10920</fpage><lpage>10929</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.23.10920-10929.2000</pub-id><pub-id pub-id-type="pmid">11069986</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00190"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Holley-Guthrie</surname><given-names>E.</given-names></name>
<name><surname>Dorsky</surname><given-names>D.</given-names></name>
<name><surname>Kenney</surname><given-names>S.</given-names></name>
</person-group><article-title>Identification of Transactivator and Nuclear Localization Domains in the Epstein-Barr Virus DNA Polymerase Accessory Protein, BMRF1</article-title><source>J. Gen. Virol.</source><year>1999</year><volume>80</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-80-1-69</pub-id><pub-id pub-id-type="pmid">9934686</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00190"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombo</surname><given-names>G.</given-names></name>
<name><surname>Villafranca</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Amino Acid Sequence of Escherichia Coli Glutamine Synthetase Deduced from the DNA Nucleotide Sequence</article-title><source>J. Biol. Chem.</source><year>1986</year><volume>261</volume><fpage>10587</fpage><lpage>10591</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)67425-3</pub-id><pub-id pub-id-type="pmid">2874141</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00190"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harth</surname><given-names>G.</given-names></name>
<name><surname>Clemens</surname><given-names>D.L.</given-names></name>
<name><surname>Horwitz</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Glutamine Synthetase of Mycobacterium Tuberculosis: Extracellular Release and Characterization of Its Enzymatic Activity (Tuberculosis/Nitrogen Metabolism/Patbogenesis/Ammonla Regulation)</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>9342</fpage><lpage>9346</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.20.9342</pub-id><pub-id pub-id-type="pmid">7937767</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00190"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>L.Z.</given-names></name>
<name><surname>Reixach</surname><given-names>N.</given-names></name>
</person-group><article-title>Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case</article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>6496</fpage><lpage>6510</lpage><pub-id pub-id-type="doi">10.1021/bi500739q</pub-id><pub-id pub-id-type="pmid">25245430</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00190"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Travis</surname><given-names>B.A.</given-names></name>
<name><surname>Peck</surname><given-names>J.V.</given-names></name>
<name><surname>Salinas</surname><given-names>R.</given-names></name>
<name><surname>Dopkins</surname><given-names>B.</given-names></name>
<name><surname>Lent</surname><given-names>N.</given-names></name>
<name><surname>Nguyen</surname><given-names>V.D.</given-names></name>
<name><surname>Borgnia</surname><given-names>M.J.</given-names></name>
<name><surname>Brennan</surname><given-names>R.G.</given-names></name>
<name><surname>Schumacher</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Molecular Dissection of the Glutamine Synthetase-GlnR Nitrogen Regulatory Circuitry in Gram-Positive Bacteria</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>3793</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31573-0</pub-id><pub-id pub-id-type="pmid">35778410</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00190"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niepmann</surname><given-names>M.</given-names></name>
<name><surname>Zheng</surname><given-names>J.</given-names></name>
</person-group><article-title>Discontinuous Native Protein Gel Electrophoresis</article-title><source>Electrophoresis</source><year>2006</year><volume>27</volume><fpage>3949</fpage><lpage>3951</lpage><pub-id pub-id-type="doi">10.1002/elps.200600172</pub-id><pub-id pub-id-type="pmid">16991206</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00190"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nowakowski</surname><given-names>A.B.</given-names></name>
<name><surname>Wobig</surname><given-names>W.J.</given-names></name>
<name><surname>Petering</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Native SDS-PAGE: High Resolution Electrophoretic Separation of Proteins with Retention of Native Properties Including Bound Metal Ions</article-title><source>Metallomics</source><year>2014</year><volume>6</volume><fpage>1068</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1039/C4MT00033A</pub-id><pub-id pub-id-type="pmid">24686569</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00190"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McMullan</surname><given-names>G.</given-names></name>
<name><surname>Naydenova</surname><given-names>K.</given-names></name>
<name><surname>Mihaylov</surname><given-names>D.</given-names></name>
<name><surname>Yamashita</surname><given-names>K.</given-names></name>
<name><surname>Peet</surname><given-names>M.J.</given-names></name>
<name><surname>Wilson</surname><given-names>H.</given-names></name>
<name><surname>Dickerson</surname><given-names>J.L.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Cannone</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Structure Determination by CryoEM at 100 KeV</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><fpage>e2312905120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2312905120</pub-id><pub-id pub-id-type="pmid">38011573</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00190"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller</surname><given-names>L.</given-names></name>
<name><surname>Salman</surname><given-names>S.</given-names></name>
<name><surname>Hoppe</surname><given-names>T.</given-names></name>
</person-group><article-title>Chemical Cross-Linking to Study Protein Self-Assembly in Cellulo</article-title><source>STAR Protoc.</source><year>2024</year><volume>5</volume><fpage>103032</fpage><pub-id pub-id-type="doi">10.1016/j.xpro.2024.103032</pub-id><pub-id pub-id-type="pmid">38652664</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00190"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Migneault</surname><given-names>I.</given-names></name>
<name><surname>Dartiguenave</surname><given-names>C.</given-names></name>
<name><surname>Bertrand</surname><given-names>M.J.</given-names></name>
<name><surname>Waldron</surname><given-names>K.C.</given-names></name>
</person-group><article-title>Glutaraldehyde: Behavior in Aqueous Solution, Reaction with Proteins, and Application to Enzyme Crosslinking</article-title><source>Biotechniques</source><year>2004</year><volume>37</volume><fpage>790</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.2144/04375RV01</pub-id><pub-id pub-id-type="pmid">15560135</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00190"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>R.J.</given-names></name>
<name><surname>Kahn</surname><given-names>J.D.</given-names></name>
<name><surname>Maher</surname><given-names>L.J.</given-names></name>
</person-group><article-title>DNA Bending by BHLH Charge Variants</article-title><source>Nucleic Acids Res.</source><year>2006</year><volume>34</volume><fpage>4846</fpage><lpage>4856</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl552</pub-id><pub-id pub-id-type="pmid">16973898</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00190"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slattery</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Dantas Machado</surname><given-names>A.C.</given-names></name>
<name><surname>Gord&#x000e2;n</surname><given-names>R.</given-names></name>
<name><surname>Rohs</surname><given-names>R.</given-names></name>
</person-group><article-title>Absence of a Simple Code: How Transcription Factors Read the Genome</article-title><source>Trends Biochem. Sci.</source><year>2014</year><volume>39</volume><fpage>381</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2014.07.002</pub-id><pub-id pub-id-type="pmid">25129887</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00190"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>J.T.</given-names></name>
</person-group><article-title>New Insights into Protein-DNA Binding Specificity from Hydrogen Bond Based Comparative Study</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>11103</fpage><lpage>11113</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz963</pub-id><pub-id pub-id-type="pmid">31665426</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00190"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rohs</surname><given-names>R.</given-names></name>
<name><surname>Jin</surname><given-names>X.</given-names></name>
<name><surname>West</surname><given-names>S.M.</given-names></name>
<name><surname>Joshi</surname><given-names>R.</given-names></name>
<name><surname>Honig</surname><given-names>B.</given-names></name>
<name><surname>Mann</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Origins of Specificity in Protein-DNA Recognition</article-title><source>Annu. Rev. Biochem.</source><year>2010</year><volume>79</volume><fpage>233</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060408-091030</pub-id><pub-id pub-id-type="pmid">20334529</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00190"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiu</surname><given-names>T.P.</given-names></name>
<name><surname>Xin</surname><given-names>B.</given-names></name>
<name><surname>Markarian</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Rohs</surname><given-names>R.</given-names></name>
</person-group><article-title>TFBSshape: An Expanded Motif Database for DNA Shape Features of Transcription Factor Binding Sites</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>D246</fpage><lpage>D255</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz970</pub-id><pub-id pub-id-type="pmid">31665425</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00190"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siggers</surname><given-names>T.</given-names></name>
<name><surname>Gord&#x000e2;n</surname><given-names>R.</given-names></name>
</person-group><article-title>Protein-DNA Binding: Complexities and Multi-Protein Codes</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>2099</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1112</pub-id><pub-id pub-id-type="pmid">24243859</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00190"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landry</surname><given-names>M.P.</given-names></name>
<name><surname>Zou</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>W.M.</given-names></name>
<name><surname>Schulten</surname><given-names>K.</given-names></name>
<name><surname>Chemla</surname><given-names>Y.R.</given-names></name>
</person-group><article-title>DNA Target Sequence Identification Mechanism for Dimer-Active Protein Complexes</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>2416</fpage><lpage>2427</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1345</pub-id><pub-id pub-id-type="pmid">23275566</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00190"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Lin</surname><given-names>K.</given-names></name>
<name><surname>Ricciardi</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Human Kaposi&#x02019;s Sarcoma Herpesvirus Processivity Factor-8 Functions as a Dimer DNA Synthesis</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>28375</fpage><lpage>28386</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400032200</pub-id><pub-id pub-id-type="pmid">15075322</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00190"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>P.C.</given-names></name>
<name><surname>Chen</surname><given-names>S.K.</given-names></name>
<name><surname>Chiang</surname><given-names>W.H.</given-names></name>
<name><surname>Ho</surname><given-names>M.R.</given-names></name>
<name><surname>Wu</surname><given-names>K.P.</given-names></name>
</person-group><article-title>Structural Basis for the Helical Filament Formation of Escherichia Coli Glutamine Synthetase</article-title><source>Protein Sci.</source><year>2022</year><volume>31</volume><fpage>e4304</fpage><pub-id pub-id-type="doi">10.1002/pro.4304</pub-id><pub-id pub-id-type="pmid">35481643</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00190"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bakker</surname><given-names>O.</given-names></name>
<name><surname>Parker</surname><given-names>M.G.</given-names></name>
</person-group><article-title>CAAT/Enhancer Binding Protein Is Able to Bind to ATF/CRE Elements</article-title><source>Nucleic Acids Res.</source><year>1991</year><volume>19</volume><fpage>1213</fpage><pub-id pub-id-type="doi">10.1093/nar/19.6.1213</pub-id><pub-id pub-id-type="pmid">2030941</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00190"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.E.</given-names></name>
<name><surname>Wu</surname><given-names>F.Y.</given-names></name>
<name><surname>Fujimuro</surname><given-names>M.</given-names></name>
<name><surname>Zong</surname><given-names>J.</given-names></name>
<name><surname>Hayward</surname><given-names>S.D.</given-names></name>
<name><surname>Hayward</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Role of CCAAT/Enhancer-Binding Protein Alpha (C/EBP&#x003b1;) in Activation of the Kaposi&#x02019;s Sarcoma-Associated Herpesvirus (KSHV) Lytic-Cycle Replication-Associated Protein (RAP) Promoter in Cooperation with the KSHV Replication and Transcription Activator (RTA) and RAP</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>600</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.1.600-623.2003</pub-id><pub-id pub-id-type="pmid">12477864</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00190"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.E.</given-names></name>
<name><surname>Wu</surname><given-names>F.Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Shamay</surname><given-names>M.</given-names></name>
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Hayward</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Early Activation of the Kaposi&#x02019;s Sarcoma-Associated Herpesvirus RTA, RAP, and MTA Promoters by the Tetradecanoyl Phorbol Acetate-Induced AP1 Pathway</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>4248</fpage><lpage>4267</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.8.4248-4267.2004</pub-id><pub-id pub-id-type="pmid">15047839</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00190"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Lukac</surname><given-names>D.M.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Reactivation and Lytic Replication of KSHV</article-title><source>Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis</source><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2007</year></element-citation></ref><ref id="B59-viruses-17-00190"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Ciustea</surname><given-names>M.</given-names></name>
<name><surname>Ricciardi</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Processivity Factor of KSHV Contains a Nuclear Localization Signal and Binding Domains for Transporting Viral DNA Polymerase into the Nucleus</article-title><source>Virology</source><year>2005</year><volume>340</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.06.017</pub-id><pub-id pub-id-type="pmid">16043206</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00190-f001"><label>Figure 1</label><caption><p>Detection of higher molecular weight PF-8 oligomers: (<bold>A</bold>). Representative electron micrograph of PF-8 using negative staining revealed two distinct conformations. White arrowheads denote ring conformation and black arrowhead denote a petal conformation. Scale bar = 25 nm (<bold>B</bold>). Quantification of the diameter of the central pore and complex of the petal and ring conformations was carried out by manually measuring. Petal pore: 5.00 &#x000b1; 0.47 nm, petal complex: 14.48 &#x000b1; 0.95 nm (n = 9), ring pore: 6.07 &#x000b1; 0.89 nm, ring complex: 13.29 &#x000b1; 0.96 nm (n = 64). (<bold>C</bold>). Denaturing gel of PF-8 (52 kDa) and GS (51.9 kDa). (<bold>D</bold>). Semi-native gel of PF-8 (filled arrowheads) and GS (open arrowheads). PF-8 forms a possible dodecamer (52 kDa &#x000d7; 12 = 624 kDa) and tetramer (52 kDa &#x000d7; 4 = 208 kDa). GS possibly forms dodecamer (622.8 kDa) and hexamer (311.4 kDa).</p></caption><graphic xlink:href="viruses-17-00190-g001" position="float"/></fig><fig position="float" id="viruses-17-00190-f002"><label>Figure 2</label><caption><p>Single-molecule EM analysis of GS and PF-8 areas: (<bold>A</bold>). Representative electron micrograph of GS with tungsten rotary shadowing. Scale bar = 50 nm. (<bold>B</bold>). Single-molecule comparison of individual molecules of GS observed with matched known structures (PDB: 8PVG). Scale bar = 5 nm. (<bold>C</bold>). Representative electron micrograph of PF-8 with tungsten rotary shadowing. (<bold>D</bold>). Single-molecule analysis of PF-8 with a proposed model representation of the observed structures. Scale bar = 5 nm (<bold>E</bold>). Dot plots of the area of PF-8 over a range of conditions: 4 &#x000b0;C, 0.5&#x02212;3 h (200 ng at room temperature), 100&#x02212;800 ng (1 h incubation at room temperature), and GS. The median values are shown for each condition by the horizontal line. Dotted and dashed lines represent cutoffs for the different PF-8 oligomers: monomer/dimer, hexamer/dodecamer, and &#x0003e;dodecamer.</p></caption><graphic xlink:href="viruses-17-00190-g002" position="float"/></fig><fig position="float" id="viruses-17-00190-f003"><label>Figure 3</label><caption><p>Mapping PF-8 DNA binding locations within KSHV lytic origin DNA. Representative electron micrographs of PF-8 in the (<bold>A</bold>). absence (unfixed) and (<bold>B</bold>). presence (fixed) of glutaraldehyde. White arrowheads denote PF-8 and black arrowheads denote streptavidin. Scale bar = 50 nm (<bold>C</bold>). Positional analysis of PF-8 binding to the OriLyt under unfixed condition (n = 427). (<bold>D</bold>). Positional analysis of PF-8 under binding to OriLyt under fixed conditions (n = 361). Aligned with the histograms is the annotated sequence of the OriLyt. Known sequences that correspond to the x-axis and binding position (bp) are highlighted. Histogram bin sizes are set to 75 bp.</p></caption><graphic xlink:href="viruses-17-00190-g003" position="float"/></fig><fig position="float" id="viruses-17-00190-f004"><label>Figure 4</label><caption><p>Modulating PF-8 DNA binding locations with nucleotide substitutions within OriLyt. Representative electron micrograph of PF-8 bound to (<bold>A</bold>). mutant 1 (M1), (<bold>B</bold>). mutant 2 (M2), or (<bold>C</bold>). mutant 3 (M3) OriLyt DNA under fixed conditions. Arrowheads denote PF-8. Scale bar = 50 nm. The DNA positional histograms of PF-8 bound to (<bold>D</bold>). mutant 1 (M1), (<bold>E</bold>). mutant 2 (M2), or (<bold>F</bold>). mutant 3 (M3) OriLyt DNA. Arrows denote the peak that contains the mutated nucleotides. Aligned with the histograms is the annotated sequence of the OriLyt with known sequences and locations of mutations. Open circles correlate with the frequency heights for the wild-type OriLyt histogram shown in <xref rid="viruses-17-00190-f003" ref-type="fig">Figure 3</xref>C. (<bold>G</bold>). Dot plot of the areas of PF-8 bound to the different OriLyt DNAs. The median values are shown for each condition by the horizontal line. Dotted and dashed lines represent cutoffs for the different PF-8 oligomers: monomer/dimer, hexamer/dodecamer, and &#x0003e;dodecamer. Kruskal&#x02013;Wallis with Dunn&#x02019;s multiple comparison test was used to determine statistical significance for protein area, **** indicates <italic toggle="yes">p</italic>-value &#x0003c; 0.0001.</p></caption><graphic xlink:href="viruses-17-00190-g004" position="float"/></fig><fig position="float" id="viruses-17-00190-f005"><label>Figure 5</label><caption><p>Characterizing OriLyt DNA structures and PF-8 complexes. Representative electron micrographs of OriLyt DNA and PF-8: (<bold>A</bold>). Single PF-8 complexes with linear and looped OriLyt. (<bold>B</bold>). Multiple PF-8 complexes with linear and looped OriLyt. (<bold>C</bold>). OriLyt DNA labeled with streptavidin and no PF-8 associated. White arrowheads denote one PF-8 complex and gray arrowheads denote two PF-8 complexes. Scale bar = 50 nm. (<bold>D</bold>). Quantification of DNA that contains no PF-8 bound, one complex of PF-8 bound, or two complexes of PF-8 bound with the wild-type, mutant 1, mutant 2, and mutant 3 DNAs under fixed conditions. The percentage of DNA molecules was calculated by dividing the number of molecules observed in each category by the total number of DNA molecules quantified and multiplying by 100. <bold>(E</bold>). Histogram of the PF-8 induced DNA bend angles.</p></caption><graphic xlink:href="viruses-17-00190-g005" position="float"/></fig><fig position="float" id="viruses-17-00190-f006"><label>Figure 6</label><caption><p>Differential analysis of PF-8 complex area and DNA binding location(s): Heat maps depict the number of PF-8 protein complexes and protein area compared to PF-8 DNA binding locations under (<bold>A</bold>). unfixed or fixed conditions with OriLyt, and fixed conditions with (<bold>B</bold>). mutant 1 (M1), (<bold>C</bold>). mutant 2 (M2), and (<bold>D</bold>). mutant 3 (M3). The protein area measurements were subdivided into three different categories: greater than a dodecamer has an area &#x0003e;325 nm<sup>2</sup>, dodecamer/hexamer has an area between 200 and 325 nm<sup>2</sup>, and a monomer/dimer area &#x0003c;200 nm<sup>2</sup> left y-axis. The mutations are indicated by arrows above the heat map. (<bold>E</bold>). Pie charts display the proportion of the different oligomeric states of PF-8 under different conditions and with different DNAs. (<bold>F</bold>). Schematic depicting the relationship between PF-8 area (shifts between 3 categories) and DNA binding location (DNA binding region) to wild-type and mutant OriLyt DNA (M1-3). The grey directionality of arrows within the graph indicates changes in binding location and shifts in protein area. Black circles denote hexamer/dodecamer PF-8 highest frequency binding location to wild-type OriLyt, and grey circles represent PF-8 highest frequency binding location to mutant OriLyt (M1-3). The black arrows above the graph indicate mutation locations.</p></caption><graphic xlink:href="viruses-17-00190-g006" position="float"/></fig><fig position="float" id="viruses-17-00190-f007"><label>Figure 7</label><caption><p>Models of PF-8&#x02019;s structures, function, and localization during KSHV lytic replication. (<bold>A</bold>). During KSHV lytic DNA replication, PF-8 is translated into the cytoplasm and subsequently translocated into the nucleus. The effective concentration of PF-8 in the nucleus increases the propensity of PF-8 to form ring complexes. PF-8 is required for KSHV DNA polymerase (POL) translocation into the nucleus. Once KSHV DNA replication proteins are localized within the nucleus, the viral replisome assembles to initiate viral replication. Light green and blue circles indicate PF-8 and purple protein denotes POL. Crystal structure [3HSL] of PF-8 dimers depicting (<bold>B</bold>). identified dimerization domains (orange) and (<bold>C</bold>). DNA polymerase binding domain (purple).</p></caption><graphic xlink:href="viruses-17-00190-g007" position="float"/></fig><table-wrap position="float" id="viruses-17-00190-t001"><object-id pub-id-type="pii">viruses-17-00190-t001_Table 1</object-id><label>Table 1</label><caption><p>KSHV processivity factor and glutamine synthase protein area.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proteins</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Median</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IQR (Lower-Upper)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n = Proteins</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">
<bold>PF-8</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">314.6 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215.2&#x02013;301.7 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">243.3 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">145.7&#x02013;279.1 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">335</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">280.2 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">244.7&#x02013;305.9 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">295.9 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">258&#x02013;326.4 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">311</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">347.8 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">266.9&#x02013;409.8 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">314</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 ng</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">274.8 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">203.1&#x02013;308.6 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">317</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 ng</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">271.2 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">236.5&#x02013;298.6 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">325</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 ng</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277.5 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">241.5&#x02013;310.9 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">351</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">800 ng</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">263.6 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">232.9&#x02013;298.5 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">430</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">
<italic toggle="yes">Molecular protein standard</italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GS</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">306.8 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">250.1&#x02013;338.0 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1112</td></tr></tbody></table><table-wrap-foot><fn><p>ng = nanogram, nm = nanometer.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00190-t002"><object-id pub-id-type="pii">viruses-17-00190-t002_Table 2</object-id><label>Table 2</label><caption><p>Preferential binding locations of KSHV processivity factor.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Primary Peak 1</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Peak 2</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Peak 3</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">DNA</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">Position</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">Motifs</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">Position</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">Motifs</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">Position</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<italic toggle="yes">Motifs</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OriLyt <break/>unfixed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">525&#x02013;600 bp (n = 37)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">375&#x02013;450 bp (n = 35)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 CAAT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75&#x02013;150 bp (n = 32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">OriLyt fixed</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">600&#x02013;675 bp<break/>(n = 32)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">2 CAAT, TATA box</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">450&#x02013;525bp<break/>(n = 31)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">AT-rich, <break/>AP-1</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">375&#x02013;450 bp<break/>(n = 25)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">3 CAAT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutant 1 fixed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">375&#x02013;450 bp<break/>(n = 32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 CAAT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">450&#x02013;525 bp (n = 32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AT-rich, <break/>AP-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">525&#x02013;600 bp (n = 25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Mutant 2 fixed</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">300&#x02013;375 bp (n = 30)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">3 CAAT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">375&#x02013;450 bp (n = 29)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">3 CAAT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">525&#x02013;600 bp (n = 28)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutant 3 fixed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75&#x02013;150 bp (n = 32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">375&#x02013;450 bp (n = 24)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 CAAT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">600&#x02013;675 bp (n = 23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 CAAT, TATA box</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00190-t003"><object-id pub-id-type="pii">viruses-17-00190-t003_Table 3</object-id><label>Table 3</label><caption><p>KSHV Processivity Factor Protein Area Bound to DNA.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DNA/Condition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Median</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IQR (Lower-Upper)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n = Proteins</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">OriLyt unfixed</td><td align="center" valign="middle" rowspan="1" colspan="1">253.0 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">215.2&#x02013;301.7 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">370</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OriLyt fixed</td><td align="center" valign="middle" rowspan="1" colspan="1">295.4 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">243.2&#x02013;353.5 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">343</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mutant 1 OriLyt</td><td align="center" valign="middle" rowspan="1" colspan="1">302.9 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">251.7&#x02013;369.6 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">384</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mutant 2 OriLyt</td><td align="center" valign="middle" rowspan="1" colspan="1">302.5 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">250.6&#x02013;362.1 nm<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">311</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutant 3 OriLyt</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">241.6 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">190.6&#x02013;296.2 nm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">298</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00190-t004"><object-id pub-id-type="pii">viruses-17-00190-t004_Table 4</object-id><label>Table 4</label><caption><p>Measured and Calculated Dimensions PF-8 Pore and PF-8 Complex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Predicted Oligomeric State</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pore Diameter <break/>(nm &#x000b1; SD)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Complex Diameter (nm &#x000b1; SD)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BMRF1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexamer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative staining</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.5 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM Makhov et al. [<xref rid="B33-viruses-17-00190" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Truncated BMRF1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetramer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crystal structure (PDB:2Z0L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K Murayama et al. [<xref rid="B31-viruses-17-00190" ref-type="bibr">31</xref>]<break/>S Nakayama et al. [<xref rid="B32-viruses-17-00190" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dodecamer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative staining</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G Harth et al. [<xref rid="B38-viruses-17-00190" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dodecamer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crystal structure (PDB: 8PVG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0-5.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC Huang et al. [<xref rid="B54-viruses-17-00190" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PF-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetramer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative staining</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0 &#x000b1; 0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.5 &#x000b1; 0.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PF-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexamer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative staining</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.1 &#x000b1; 0.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.3 &#x000b1; 0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap></floats-group></article>